Abstract
Though extrapulmonary small cell carcinoma was first described over 80 years ago, definitive treatment recommendations are lacking. The treatment strategies commonly utilized are extrapolated from pulmonary small cell carcinoma experience. A better understanding of this entity is needed to improve management approach. The University of Kansas tumor registry was reviewed from 1990 to 2013. Thirty-five cases met the inclusion and exclusion criteria for review. Age, gender, smoking status, weight loss, metastatic disease-related data, stage, performance status (PS), treatment received, and survival data were collected. Patients were evaluated with a variety of primary locations of disease including GI tract (29 %), GU tract (35 %), Gyn organs (17 %), head and neck (14 %), and unknown primary (9 %). Several sites of metastatic disease were noted, with 57 and 43 % of patients meeting criteria for limited disease (LD) and extensive disease (ED), respectively. Chemotherapy, surgery, and radiation were used in several different regimens, with small cell lung cancer-type regimens incorporating a platinum and etoposide being the most common (74 %). Patients with LD had a median survival of 36 months compared with 5 months in patients with ED (p < 0.0001). Among different primary sites, patients with GU and Gyn LD tumors had best median survival of 36 months. Among other variables that were examined with respect to their poor prognostic significance, PS >2 (p = 0.001) and one or fewer number of treatment modalities especially in LD (p = 0.0005) were found to be associated significantly with mortality. GI and GU tract tumors were the most common primary sites of disease in our retrospective review. Survival varied according to stage, PS, site of primary disease, use of chemotherapy, and number of treatment modalities used. Further studies are needed to better understand this rare disorder and optimize management approach.
Similar content being viewed by others
References
Brennan SM. Should extrapulmonary small cell cancer be managed like small cell lung cancer? Cancer. 2010;116(4):888–95. doi:10.1002/cncr.24858.
Lee SS. Extrapulmonary small cell carcinoma: single center experience with 61 patients. Acta Oncol. 2007;46(6):846–51. doi:10.1080/02841860601071893.
Cicin I. Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma: a retrospective single-center study. Cancer. 2007;110(5):1068–76. doi:10.1002/cncr.22887.
Kim JH. Extrapulmonary small-cell carcinoma: a single-institution experience. Jpn J Clin Oncol. 2004;34(5):250–4.
Choong NWW. Small cell carcinoma of the urinary bladder. Mayo Clinic Experi Cancer. 2005;103(6):1172–8. doi:10.1002/cncr.20903.
Casas F. Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis. Cancer. 1997;80(8):1366–72. doi:10.1002/(sici)1097-0142(19971015)80:8<1366:aid-cncr2>3.0.co;2-d.
Soto DE (2007) Limited-stage extrapulmonary small cell carcinoma: outcomes after modern chemotherapy and radiotherapy. Cancer J (Sudbury, Mass). 13(4):243–246. doi:10.1097/PPO.0b013e31813ffe7c.
Cicin I. Extrapulmonary small cell carcinoma localized in lymph nodes: is it a different clinical entity? Acta Oncol. 2009;48(3):354–60. doi:10.1080/02841860802495370.
van der Heijden HFM (2005) Extrapulmonary small cell carcinoma. Southern medical journal (Birmingham, Ala). 98(3):345–349.
Pignon JP. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. New England J Med. 1992;327(23):1618–24. doi:10.1056/nejm199212033272302.
Clark R. (1998) Small-cell lung cancer: treatment progress and prospects. Oncology (Williston Park, NY). 12(5):647–658; discussion 61–63.
Haider K. Extrapulmonary small cell cancer: a Canadian province’s experience. Cancer. 2006;107(9):2262–9. doi:10.1002/cncr.22235.
Lo Re G. Extrapulmonary small cell carcinoma: a single-institution experience and review of the literature. Ann Oncol. 1994;5(10):909–13.
Lee SY, Hsu HH, Lin HY, Chen YC, Wong YC, Wang LJ, et al. Factors associated with the survival of patients with primary small cell carcinoma of the kidney. Int J Clin Oncol. 2013;18(1):139–47. doi:10.1007/s10147-011-0355-7.
Hatoum GF, Patton B, Takita C, Abdel-Wahab M, LaFave K, Weed D, et al. Small cell carcinoma of the head and neck: the university of Miami experience. Int J Radiat Oncol Biol Phys. 2009;74(2):477–81. doi:10.1016/j.ijrobp.2008.08.014.
Brenner B, Tang LH, Klimstra DS, Kelsen DP. Small-cell carcinomas of the gastrointestinal tract: a review. Int J Clin Oncol. 2004;22(13):2730–9. doi:10.1200/JCO.2004.09.075.
Hoskins PJ, Swenerton KD, Pike JA, Lim P, Aquino-Parsons C, Wong F, et al. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. Int J Clin Oncol. 2003;21(18):3495–501. doi:10.1200/JCO.2003.01.501.
Acknowledgments
This work was supported by a CTSA grant from NCRR and NCATS awarded to the University of Kansas Medical Center for Frontiers: the Heartland Institute for Clinical and Translational Research # KL2TR000119. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, NCRR, or NCATS.
Conflict of interest
The authors declare that they have no conflict of interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dakhil, C.S.R., Wick, J.A., Kumar, A.K.L. et al. Extrapulmonary small cell carcinoma: the University of Kansas experience and review of literature. Med Oncol 31, 187 (2014). https://doi.org/10.1007/s12032-014-0187-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-014-0187-1